Revive Therapeutics (TSE:RVV) has released an update.
Revive Therapeutics Ltd. is advancing a study on Bucillamine as a potential treatment for nerve agent exposure, with results expected by August 2024. The study, conducted in partnership with Canada’s Defence R&D agency, aims to assess Bucillamine’s effectiveness in mitigating brain injury caused by nerve agents, which are highly toxic and used in chemical warfare. Promising results could lead to further studies for FDA and Health Canada approvals for Bucillamine’s use in treating nerve agent and pesticide poisoning.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
